Tissue Regenix Group PLC Notice of Results (2015Q)
September 08 2017 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 2015Q
Tissue Regenix Group PLC
08 September 2017
Tissue Regenix Group plc
Notice of Interim Results and Capital Markets Day
Leeds, 8 September 2017 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or "The Group") the regenerative medical devices
company, today gives notice that it will announce its interim
results for the six months ending 31 June 2017, on Thursday 28
September 2017.
The Group will also host a Capital Markets Day in London on
Thursday 12 October where it will provide an update on business
activities and the integration of CellRight Technologies, with
presentations from top level UK and US management.
For more Information:
Tissue Regenix Group plc Tel: 0330 430
Caitlin Pearson, Corporate Communications 3073
Director
=========================================== ==============
Jefferies International Ltd Tel: 020 7029
Simon Hardy / Christopher Binks 8000
FTI Consulting Tel: 020 3727
Brett Pollard/ Mo Noonan/ Rob 1000
Winder
=========================================== ==============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORZMGGLKRVGNZG
(END) Dow Jones Newswires
September 08, 2017 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024